Extrahepatic spread of hepatocellular carcinoma

Panminerva Medica

Volumn 54, Issue 4, 2012, Pages 313-322

  Cabibbo, G ^a   Compilato, D ^a   Genco, C ^a   Campisi, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Carcinoma, hepatocellular; Neoplasm metastasis; Sorafenib

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; SORAFENIB;

ANIMAL; ARTICLE; ENZYMOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROGNOSIS; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PROTEIN KINASE INHIBITORS;

EID: 84871597601     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective. Oncologist 2010; 15( Suppl 4): 5-13.
3. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42( Suppl3): S206-214.
4. El-Serag HB, Dávila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003; 139: 817-23.
5. Cabibbo G, Craxi A. Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci 2010; 14: 352-5.
6. Lata J. Chronic liver diseases as liver tumor precursors. Dig Dis 2010; 28: 596-9.
7. Powell EE, Jonsson JR, Clouston AD: Metabolic factors and nonalcoholic fatty liver disease as co-factors in other liver diseases. Dig Dis 2010; 28: 186-91.
8. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010; 52: 252-257.
9. Mancuso A. Hepatocellular carcinoma in thalassemia: A critical review. World J Hepatol 2010; 2: 171-4.
10. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36. (Pubitemid 43112690)
11. Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. Am J Med 2007; 120:194-202. (Pubitemid 46341174)
12. Camma C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: None is the winner. Liver Int 2009; 29: 478-80.
13. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51: 1274-83.
14. Cottone M, Virdone R, Fusco G, Orlando A, Turri M, Caltagirone M et al. Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. A comparison of natural history and surgical treatment. Gastroenterology 1989;96:1566-71. (Pubitemid 19138702)
15. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The cancer of the liver italian program (CLIP) investigators. Hepatology 1998; 28: 751-5.
16. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24. (Pubitemid 34183954)
17. Okuda K, Obata H, Nakajima Y, Ohtsuki T, Okazaki N, Ohnishi K. Prognosis of primary hepatocellular carcinoma. Hepatology 1984;4:3S-6S. (Pubitemid 14014186)
18. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
19. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999;31:133-41. (Pubitemid 29287619)
20. Schoniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001;48:103-9. (Pubitemid 32042649)
21. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002;94:1760-9. (Pubitemid 34241115)
22. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002;20:1527-36. (Pubitemid 34260532)
23. Tournoux-Facon C, Paoletti X, Barbare JC, Bouche O, Rougier P, Dahan L et al. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol 2011; 54: 108-14.
24. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
25. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
26. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
27. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62: 479-83.
28. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-4.
29. Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993;17:389-94. (Pubitemid 23072812)
30. Madden MV, Krige JE, Bailey S, Beningfield SJ, Geddes C, Werner ID et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993;34:1598-600. (Pubitemid 23341855)
31. Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol 1994;26:66-8. (Pubitemid 24140196)
32. Martinez Cerezo FJ, Tomas A, Donoso L, Enriquez J, Guarner C, Balanzo J et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994;20:702-6. (Pubitemid 24216879)
33. [No authors listed]. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995; 332: 1256-61.
34. Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995; 21: 1535-42.
35. Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L et al. Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109: 917-22.
36. Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998;16:411-7. (Pubitemid 28135581)
37. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442-7. (Pubitemid 28197039)
38. Riestra S, Rodriguez M, Delgado M, Suarez A, Gonzalez N, de la Mata M et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol 1998;26:200-3. (Pubitemid 28211364)
39. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578-83. (Pubitemid 28264682)
40. Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998; 352: 17-20.
41. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88: 1986-91.
42. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-8. (Pubitemid 30033689)
43. Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 2000;95:218-22. (Pubitemid 30041563)
44. Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002;36:1221-6. (Pubitemid 35253439)
45. Barbare JC, Bouche O, Bonnetain F, Raoul JL, Rougier P, Abergel A et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005;23:4338-46. (Pubitemid 46207007)
46. Sarin SK, Kumar M, Garg S, Hissar S, Pandey C, Sharma BC. High dose vitamin K3 infusion in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2006;21:1478-82. (Pubitemid 44154720)
47. Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007;45:9-15. (Pubitemid 46144359)
48. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial. World J Gastroenterol 2007; 13: 3164-70.
49. Barbare JC, Bouche O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R et al. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer 2009, 45: 1788-97.
50. Ishikawa T, Ichida T, Sugitani S, Tsuboi Y, Genda T, Sugahara S et al. Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol 2001;16:452-9. (Pubitemid 32397659)
51. Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-91. (Pubitemid 34977180)
52. Villa E, Ferretti I, Grottola A, Buttafoco P, Buono MG, Giannini F et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001;84:881-5. (Pubitemid 32385828)
53. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71. (Pubitemid 34454013)
54. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9. (Pubitemid 34607087)
55. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000; 31: 840-5.
56. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 2001;34:529-34. (Pubitemid 32786644)
57. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002;50:881-5. (Pubitemid 34539054)
58. Cilio U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 2004;40:124-31. (Pubitemid 38064721)
59. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411-8. (Pubitemid 40299100)
60. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707-16. (Pubitemid 40462931)
61. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G et al. Prospective validation of the barcelona clinic liver cancer staging system. J Hepatol 2006; 44: 723-31.
62. Camma C, Di Marco V, Cabibbo G, Latteri F, Sandonato L, Parisi P et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008;28:62-75. (Pubitemid 351782806)
63. Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouche O, Raoul JL et al. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol 2008;19:1117-26. (Pubitemid 351796337)
64. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, Saltz LL et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 2010; 28: 2889-95.
65. Katyal S, Oliver JH, 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216:698-703. (Pubitemid 30660840)
66. Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, Sato T et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005;20:1781-7. (Pubitemid 43961087)
67. Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007;13:414-20. (Pubitemid 46178976)
68. Dayan D, Vered M. Comment on "Hepatocellular carcinoma: An inflammation-associated cancer with an increased incidence of oral metastases". Oral Oncol 2011; 47: 76.
69. Teshigawara K, Kakizaki S, Sohara N, Hashida T, Tomizawa Y, Sato K et al. Solitary mandibular metastasis as an initial manifestation of hepatocellular carcinoma. Acta Med Okayama 2006;60:243-7. (Pubitemid 44352469)
70. Lianes F, Sanz-Ortega J, Suarez B, Sanz-Esponera J. Hepatocellular carcinomas diagnosed following metastasis to the oral cavity. Report of 2 cases. J Periodontal 1996;67:717-9. (Pubitemid 126613050)
71. Chin A, Liang TS, Borislow AJ. Initial presentation of hepatocellular carcinoma as a mandibular mass: case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:457-60. (Pubitemid 128641993)
72. Ramon Ramirez J, Seoane J, Montero J, Esparza Gomez GC, Cerero R. Isolated gingival metastasis from hepatocellular carcinoma mimicking a pyogenic granuloma. J Clin Periodontal 2003;30:926-9. (Pubitemid 38019386)
73. Li R, Walvekar RR, Nalesnik MA, Gamblin TC. Unresectable hepatocellular carcinoma with a solitary metastasis to the mandible. Am Surg 2008;74:346-9. (Pubitemid 351489601)
74. Huang SF, Wu RC, Chang JT, Chan SC, Liao CT, Chen IH et al. Intractable bleeding from solitary mandibular metastasis of hepatocellular carcinoma. World J Gastroenterol 2007;13:4526-8. (Pubitemid 47412422)
75. Kamatani T, Tatemoto Y, Tateishi Y, Yamamoto T. Isolated metastasis from hepatocellular carcinoma to the mandibular condyle with no evidence of any other metastases: A case report. Br J Oral Maxillofac Surg 2008; 46: 499-501.
76. Fujihara H, Chikazu D, Saijo H, Suenaga H, Mori Y, lino M et al. Metastasis of hepatocellular carcinoma into the mandible with radiographic findings mimicking a radicular cyst: A case report. J Endod; 36: 1593-6.
77. Vitale AR, Compilato D, Coletti G, Calvisi G, Ciuffitelli V, Barbera D et al. Metastatic hepatocellular carcinoma of the parotid region without lung metastasis: A case report. Int J Oral Maxillofac Surg 2009; 38: 696-8.
78. Nagao Y, Cho A, Yamamoto H, Kainuma O, Gunji H, Miyazaki A et al. Hepatocellular carcinoma with pharyngeal metastasis: Report of a case. Surg Today 2008; 38: 1060-2.
79. Kahn J, Kniepeiss D, Langner C, Wagner D, Iberer F, Tscheliessnigg K. Oesophageal metastases of hepatocellular carcinoma after liver transplantation. Transpl Int 2010; 23: 438-9.
80. Izquierdo J, Armengot M, Cors R, Perez A, Basterra J. Hepatocarcinoma: metastasis to the nose and paranasal sinuses. Otolaryngol Head Neck Surg 2000; 122:932-3. (Pubitemid 30412670)
81. Goto T, Dohmen T, Miura K, Ohshima S, Yoneyama K, Shibuya T et al. Skull metastasis from hepatocellular carcinoma with chronic hepatitis B. World J Gastrointest Oncol; 2: 165-8.
82. Kanai R, Kubota H, Terada T, Hata T, Tawaraya E, Fujii K. Spontaneous epidural hematoma due to skull metastasis of hepatocellular carcinoma. J Clin Neurosci 2009; 16: 137-40.
83. Nava VE, Liu ML. Hepatocellular carcinoma metastases to facial subcutaneous tissue. Arch Pathol Lab Med 2010; 134: 809.
84. Aung TH, Po YC, Wong WK. Hepatocellular carcinoma with metastasis to the skull base, pituitary gland, sphenoid sinus, and cavernous sinus. Hong Kong Med J 2002; 8: 48-51.
85. Choi HJ, Cho BC, Sohn JH, Shin SJ, Kim SH, Kim JH et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol 2009; 91: 307-13.
86. Kim IT, Na SC, Jung BY. Hepatocellular carcinoma metastatic to the orbit. Korean J Ophthalmol 2000; 14: 97-102.
87. Magana M, Gomez LM. Skin metastasis from hepatocarcinoma. Am J Dermatopathol 2009; 31: 502-5.
88. Lazaro M, Allende I, Raton JA, Acebo E, Diaz-Perez JL. Cutaneous metastases of hepatocellular carcinoma. Clin Exp Dermatol 2009; 34: e567-569.
89. Kaibori M, Morita M, Tagami S, Uchida Y, Tanaka H, Yoshioka K et al. Cutaneous and colonic metastases after resection of hepatocellular carcinoma. Dig Dis Sci 2007;52:1114-7. (Pubitemid 46481263)
90. Liu WC, Lui KW, Ho MC, Fan SZ, Chao A. Right ventricular exclusion for hepatocellular carcinoma metastatic to the heart. J Cardiothorac Surg 2010; 5: 95.
91. D'Antonio A, Caleo A, Caleo O, Addesso M, Boscaino A. Hepatocellular carcinoma metastatic to the kidney mimicking renal oncocytoma. Hepatobiliary Pancreat Dis Int 2010; 9: 550-2.
92. Kim DH, Eun JR, Moon HJ, Oh HJ, Kim YK, Jang BI et al. [ A case of peritoneal seeding from a ruptured hepatocellular carcinoma with direct invasion into the stomach causing gastrointestinal hemorrhage]. Korean J Gastroenterol 2009; 53: 194-7.
93. Murakami M, Nagano H, Kobayashi S, Marubashi S, Noda T, Tomimaru T et al. [ A case of hepatocellular carcinoma with gall bladder metastasis. Gan To Kagaku Ryoho 2008; 35: 2089-91.
94. Yan ML, Wang YD, Lai ZD, Tian YF, Chen HB, Qiu FN et al. Pedunculated hepatocellular carcinoma and splenic metastasis. World J Gastroenterol 2009; 15: 5239-41.
95. Fitzhugh VA, Kim SA, Borcich A, Zhu H, Wu M, Szporn AH et al. Metastatic hepatocellular carcinoma presenting as a pancreatic mass by computed tomography scan and mimicking a primary neuroendocrine tumor: A potential pitfall in aspiration cytology. Diagn Cytopathol 2009; 37: 915-9.
96. Somerset H, Witt JP, Kleinschmidt-Demasters BK. Hepatocellular carcinoma metastases to the epidural space. Arch Pathol Lab Med 2009; 133: 1975-80.
97. Batson OV. The function of the vertebral veins and their role in the spread of metastases. 1940. Clin Orthop Relat Res 1995: 4-9.
98. Thomas MB, Zhu AX: Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005;23:2892-9. (Pubitemid 46224106)
99. Cabibbo G, Craxi A: Hepatocellular cancer: Optimal strategies for screening and surveillance. Dig Dis 2009; 27: 142-7.